Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration

January 2009
BMC Psychiatry;2009, Vol. 9, p80
Academic Journal
No abstract available.


Related Articles

  • Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: Findings from a Veterans Affairs-based population. Chienning Hsu; Ried, L. Douglas; Bengtson, Michael A.; Garman, Patrick M.; McConkey, Joel R.; Rahnavard, Farzad // Journal of the American Pharmacists Association: JAPhA;May/Jun2008, Vol. 48 Issue 3, p393 

    Objectives: To describe the proportions of veterans living with schizophrenia-related disorders monitored for dyslipidemia and hyperglycemia and to investigate whether the likelihood of metabolic dysregulation monitoring was influenced by veterans' sociodemographic characteristics, preswitch...

  • Monitoring Metabolic Side Effects when Initiating Treatment with Second-Generation Antipsychotic Medication. Weissman, Ellen; Jackson, Carlos; Schooler, Nina; Goetz, Ray; Essock, Susan // Clinical Schizophrenia & Related Psychoses;Jan2012, Vol. 5 Issue 4, p201 

    Objective: Published guidelines recommend metabolic monitoring for patients prescribed second-generation antipsychotic (SGA) medications. This study determined monitoring rates, and examined predictors of monitoring, for total cholesterol and weight among patients prescribed SGAs during a period...

  • Schizophrenia and Related Disorders.  // Current Medical Literature: Psychiatry;2006, Vol. 17 Issue 2, p48 

    Presents abstracts of research in schizophrenia and related disorders. "Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol"; "QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical...

  • Predictors of metabolic parameter monitoring in adolescents on antipsychotics in a primary care setting. Ghate, Sameer R.; Porucznik, Christina A.; Said, Qayyim; Hashibe, Mia; Joy, Elizabeth; Brixner, Diana I. // Mental Health in Family Medicine;2012, Vol. 9 Issue 3, p137 

    Objective To assess the frequency and predictors of regular monitoring of metabolic parameters as recommended by the American Diabetes Association (ADA)/American Psychiatric Association (APA) guidelines in adolescents receiving antipsychotics compared with an untreated comparison group in a...

  • Advances in Therapeutic Drug Monitoring of Atypical Antipsychotic Drugs. Raggi, M. A.; Mandrioli, R.; Pucci, V.; Sabbioni, C. // Medicinal Chemistry Reviews - Online;Jul2004, Vol. 1 Issue 3, p299 

    The introduction in clinical practice of new antipsychotic drugs neurologically safer and with a broader spectrum of efficacy than �classical� neuroleptics has brought about significant improvement in the therapy of schizophrenic patients. These second-generation antipsychotics usually...

  • Naturalistic Studies of Second Generation Antipsychotics in the Treatment of Schizophrenia. Sebastian, C. Simon; Glazer, William; Buckley, Peter F. // Current Medicinal Chemistry;Feb2004, Vol. 11 Issue 3, p329 

    Undoubtedly, the pharmacological treatment of schizophrenia has changed dramatically over the last 10 years. Large, double-blind, placebo-controlled trials have ushered the availability of each new antipsychotic. However, there has been an information lag because of the relative paucity of long...

  • Clinical News. Conley, Robert R. // Clinical Schizophrenia & Related Psychoses;Jul2007, Vol. 1 Issue 2, p127 

    The article discusses new indications for antipsychotic use in adolescents. It is stated that early and suitable treatment with antipsychotics is important for patients with first-episode schizophrenia. There are many possible safety issues that should be considered and properly addressed. In an...

  • Developing A Policy For Second-Generation Antipsychotic Drugs. Rosenheck, Robert A.; Sernyak, Michael J. // Health Affairs;Sep2009 Supplement, Vol. 28, p782 

    Second-generation antipsychotics (SGAs) have replaced older drugs in the treatment of schizophrenia; their costs in the United States have reached $13 billion a year. Recent research, however, shows that their net risk/benefit profiles are no better than some older, cheaper drugs. Stepped...

  • Metabolic syndrome risk in patients prescribed atypical antipsychotics. McKnight, Whitney; Milone, Angelo // Psychiatric Annals;Jul2011, Vol. 41 Issue 7, p347 

    The article focuses on the need for coordination among clinicians in dealing with the risk for metabolic disorders among mentally-ill patients who are taking second-generation antipsychotic (SGA) drugs. It highlights the warning by the U.S. Food and Drug Administration on the adverse effects of...

  • The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy. Montgomery, William; Li Liu; Stensland, Michael D.; Hai Bo Xue; Treuer, Tamas; Ascher-Svanum, Haya // ClinicoEconomics & Outcomes Research; 

    Background: This article describes the personal, societal, and economic burden attributable to schizophrenia in the People's Republic of China and highlights the potential for effective outpatient treatment to reduce this burden given recent changes in the Chinese health care system. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics